Search U.S. Product Recalls Database

Showing 2761–2780 of 14370 results

Sort:

NAD+ Nicotinamide Dinucleotide (Olympia) - Reconstitution Failure (2022)

Failed Reconstitution time

FDAApr 4, 2022Nationwide• Olympia Compounding Pharmacy dba Olympia Pharmacy

NB-243 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated

Class IIModerate

FDAApr 4, 2022Nationwide• Olympia Compounding Pharmacy dba Olympia Pharmacy

Stay Informed

Search Product Recalls

NAD+ Nicotinamide Dinucleotide (Olympia) - Reconstitution Failure (2022)

NB-243 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

T-50 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

BIMIX-3 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

PGE-1 Alprostadil (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

ST-1 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

Hydroxocobalamin B12 (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

AT-1 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

PGE-2 Alprostadil (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

Ultratest Testosterone (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

RE-1 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

QM-4 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

Formula F2 (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

RE-2 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

ST-2 Medication (Olympia Pharmacy) – CGMP Monitoring Issues (2022)

SB-5 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

QM-3 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

FA Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)

Sincalide Lyophilized Powder (Olympia) - CGMP Monitoring Issues (2022)

SB-4 Papaverine Phentolamine (Olympia) - CGMP Monitoring Issues (2022)